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with bone oligometastases treated concurrently
with thoracic three-dimensional radiotherapy and
chemotherapy
Wei-Wei Ouyang†, Sheng-Fa Su†, Zhu Ma†, Yin-Xiang Hu, Bing Lu*, Qing-Song Li, Yi-Chao Geng and Hui-Qin LiAbstract
Background: To evaluate the efficacy of three-dimensional radiotherapy for non-small cell lung cancer (NSCLC)
patients with bone metastases.
Methods: Clinical data for 95 NSCLC patients with bone metastases were collected and prognostic factors were
analyzed. All patients received radiation to their thoracic primary tumor and ≥2 cycles of chemotherapy.
Results: Of these 95 patients, 47 patients had only bone metastases and 48 had both bone metastases and other
organ metastases. Univariate analysis showed that factors that statistically significantly contributed to patients
having longer overall survival (OS) included receiving a radiation dose to the primary tumor ≥63 Gy, responding to
treatment and receiving ≥4 cycles of chemotherapy (p = 0.001, p = 0.037 and p = 0.009, respectively). A radiation
dose to the primary tumor ≥63 Gy remained significant for patients with bone metastases only as well as those
with bone and other organ metastases when they were analyzed separately (p = 0.045 and p = 0.012, respectively).
For patients with bone metastases only, those with T1-2 tumors had longer OS than those with T3-4 (p = 0.048);
and patients who received ≥4 cycles chemotherapy compared with those who received <4 cycles had similar OS
(p = 0.385). On multivariate analysis, only a radiation dose ≥63 Gy (p = 0.028) and having only bone metastases
(p = 0.006) were independent prognostic factors for better OS.
Conclusions: A radiation dose to the primary tumor ≥63 Gy and having only bone metastases were associated
with better OS in NSCLC patients with bone metastases. For patients with bone metastases only, besides radiation
dose, T status was also correlated with OS, whereas the number of chemotherapy cycles was not. Therefore,
aggressive thoracic radiation may play an important role in improving OS.
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Approximately 55% of patients newly diagnosed with
non-small cell lung cancer (NSCLC) have distant metas-
tases [1]. System chemotherapy is the main treatment
modality for stage IV NSCLC. The response rate to
platinum-based doublet chemotherapy for stage IV
NSCLC is approximately 30–40%, and this treatment* Correspondence: lbgymaaaa@sohu.com
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unless otherwise stated.produces a median survival time (MST) of 8–10 months
[2,3]. Moreover, the survival duration has not obviously
increased with chemotherapy treatment for stage IV
NSCLC patients over the past 10–15 years [4]. Different
third-generation chemotherapy regimens have similar ef-
ficacy, indicating that the efficacy of a chemotherapeutic
approach has reached a plateau. However, the metastatic
status of NSCLC patients shows variability, and how to
treat stage IV NSCLC patients with radiation therapy is
not well defined.
We investigated clinical metastases features in 546 pa-
tients with stage IV NSCLC and 53.8% (294/546) ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,












Male 68 18 18 32
Female 27 2 9 16
Age (years)
Range (median) 30 ~ 78(59) 40 ~ 78(62) 41 ~ 72(59) 30 ~ 76(58)
<60 50 9 14 27
≥60 45 11 13 21
Pathological type
Squamous 31 7 10 14
Non-squamous 64 13 17 34
T stage
T1–2 36 11 10 15
T3–4 59 9 17 33
N stage
N0–1 14 3 4 7
N2–3 81 17 23 41







70 39 5 9 25
>70 56 15 18 23
Prescribed dose
Range (median) 9 ~ 76(63) 23 ~ 76(63) 9 ~ 72(63) 9 ~ 68(58)
<63 Gy 47 10 8 29




CR + PR 66 15 18 33
SD + PD 29 5 9 15
Chemotherapy
Range (median) 2 ~ 5(4) 2 ~ 4(3) 2 ~ 4(4) 2 ~ 5(4)
2-3 cycles 43 10 9 24
≥4 cycles 52 10 18 24
Radiation to
metastases
Yes 15 9 3 3
No 80 11 24 45
Note: GTV from a minimum ~maximal value cm3 (median).
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mon metastatic site [5]. Patients with lung cancer who
develop bone metastases have a poor prognosis; the
MST ranges from 7.0 to 8.0 months [6,7]. Recent publi-
cations also have reported that radiation of the primary
tumor may prolong survival time in certain patients with
stage IV NSCLC [8-10]. In this context, we performed
this study to investigate outcomes and prognostic factors
for NSCLC patients with bone oligometastases at diag-
nosis, who received radiation therapy for their thoracic
primary tumor.
Methods
Patient selection and pretreatment evaluation
Ninety-five patients who came to the hospital from
January 2003 to July 2010 with stage IV NSCLC and
who fulfilled all of the following criteria were included
in this study. (1) Pathologically or cytologically con-
firmed diagnosis of NSCLC; (2) newly diagnosed stage
IV disease according to the staging system of the 2002
American Joint Committee on Cancer; (3) aged between
18–80 years; (4) Karnofsky Performance Status (KPS)
score ≥70%, as well as a weight loss of no more than
10% during the 6 months prior to therapy; (5) bone me-
tastases at ≤5 sites; (6) adequate bone marrow, liver and
renal function; (7) no radiotherapy or chemotherapy
contraindications; (8) thoracic radiotherapy using either
three-dimensional conformal radiation therapy (3D-CRT)
or intensity-modulated radiation therapy (IMRT); and (9)
treatment with at least two cycles of chemotherapy.
Exclusion criteria were as follows: (1) history of a thor-
acic operation, radiotherapy or chemotherapy; (2) preg-
nant or lactating; and (3) previous malignancy or other
concomitant malignant disease. The Institutional Review
Board of the Affiliated Hospital of Guiyang Medical
College and Guizhou Cancer Hospital China approved
this study, and the informed consent was obtained from
all patients.
Pretreatment evaluation included a complete physical
examination and hematologic and biochemistry profiles.
Fiberoptic bronchoscopy examination and contrast-
enhanced computed tomography (CT) of chest were
performed to accurately evaluate the extent of the pri-
mary tumor and regional lymph nodes. Bone scintig-
raphy, contrast-enhanced CT of the abdominal region
and magnetic resonance imaging (MRI) of the brain
were routinely used to detect distant metastases. If a
PET/CT scan was done, then bone scintigraphy and
contrast-enhanced CT scans of the abdominal region
were not necessary. Additional investigations were per-
formed if indicated. Positive PET/CT or bone scan find-
ings for bone metastases also required other additional
radiologic confirmation (e.g., MRI of bone). Clinical
characteristics of the 95 patients are detailed in Table 1.Radiotherapy protocol
All patients were immobilized in the supine position
with a T bar, wing board and Vac-lock cradle. Images
with contrast were obtained from the CT simulator for
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with serial 5-mm slices from the hyoid bone through the
third lumbar vertebra. All patient 3D-CRT or IMRT
treatment plans were performed using the ADAC pinna-
cle3 planning system (version 7.4 f ) and dose distribu-
tion was computed with tissue heterogeneity correction.
The gross tumor volume (GTV) included thoracic pri-
mary tumors and hilar or mediastinal lymph nodes with
a short-axis diameter of at least 1 cm on CT, and the
planning target volume (PTV) was defined as the GTV
plus a 1.5-cm margin for setup uncertainty and respira-
tory motion. Radiation was delivered with a linear accel-
erator using 6 MV photons. V20 (percentage of the total
lung volume receiving ≥20 Gy), the maximal point dose
of spinal cord and mean esophagus dose were required
to be ≤32%, 50 Gy and ≤35 Gy, respectively, for the indi-
vidual treatment plan. The prescribed dose encompassed
at least 95% of PTV. Thoracic radiation was delivered in
2 Gy daily fractions (5 days each week) and patients re-
ceived thoracic radiation of at least a dose of 40 Gy in
20 fractions. Thoracic radiation treatment was imple-
mented concurrently with chemotherapy. The fraction-
ated radiotherapy dose for metastatic tumors ranged
from 3 to 10 Gy/fraction with 1 fraction/day, and the
total prescribed radiotherapy dose for metastatic lesions
ranged from 20 to 60 Gy. Radiation to metastatic lesions
was implemented concurrently or sequentially with
chemotherapy.
Chemotherapy protocol
All patients received platinum-based doublet chemother-
apy and the selection of regimens was according to prior
studies [3,11]. The commonly used regimens and usage
were as follows: 135–175 mg of paclitaxel (P) per square
meter of body surface area (mg/m2) or 75 mg/m2 of do-
cetaxel (D) administered on day 1, followed by 80 mg/
m2 of cisplatinum (C) or carboplatin (Cb) at a dose of
300–350 mg/m2 administrated on day 2, and vinorelbine
(V) at a dose of 25 mg/m2, administered on days 1 and 8
during thoracic radiotherapy given every 21–28 days.
Concurrent thoracic radiation was given within 1 week
following the start of chemotherapy. After completion of
thoracic radiotherapy, patients demonstrating a response
or stable disease continued on chemotherapy for up to
4–6 cycles, whereas patients who experienced progres-
sive disease or unacceptable toxicity were transferred to
second-line therapy. Platinum and taxane-based chemo-
therapy were the main regimens used in the current
study. PC or PCb regimens were used in 38 cases, DC or
DCb regimens in 51 cases and the VC regimen in six
cases. In total, 45% of patients received two or three cy-
cles of chemotherapy, and 55% of patients received four
or five cycles of chemotherapy. The total number of cy-
cles was 315 (mean per patient, 3.3).Statistical analysis
The Statistical Package for Social Sciences, version 13.0
(SPSS, Chicago, IL) was used for statistical analysis. The
Kaplan-Meier method was used to calculate overall sur-
vival (OS) and compared using the log-rank test. Factors
with p <0.1 were included in multivariate analysis. The
Cox model was used for multivariate analysis of OS. All
statistical tests were two-sided, and p <0.05 was consid-
ered statistically significant.
Results
The last follow-up was in November 2012. The follow-
up periods ranged from 2.0 to 76.0 (median, 11.0)
months. At the time of the last follow-up, 92 patients
had died, one patient was lost to follow-up at 20 months
after finishing treatment (who was in the group of bone
and other organ metastases) and two patients were still
alive with survival times of 47 and 76 months. For all pa-
tients, the MST was 11.0 months (95% confidence inter-
val (CI), 8.5–13.5) and the 1-, 2-, and 3-year OS rates
were 43.6, 16.8 and 8.5%, respectively. The 1-, 2- and
3-year OS rates were 58.1, 24.8 and 15.8%, respectively
for patients with bone metastases only and the MST was
14 months (95% CI, 10.3–17.7). For patients who had
bone and other organ metastases, the 1-, 2- and 3-year
OS rates were 31.8, 9.8 and 0.0%, respectively and the
MST was 8 months (95% CI, 5.6–10.4) (χ2 = 10.092,
p = 0.001). For patients with bone metastases only, the
OS for patients with metastases in 1–2 sites was similar
to those with metastases in ≥3 sites (χ2 = 0.029, p = 0.866).
The median GTV was 159 cm3 (17–628 cm3). The 1-, 2-,
and 3-year OS rates for patients with GTV <159 cm3
compared with those with GTV ≥159 cm3 were 54.8
versus 37.5%, 19.4 versus 9.4% and 11.9 versus 3.1%,
respectively, and the MST was 14 months (95% CI,
9.6–18.4) versus 9 months (95% CI, 6.7–11.3), respectively
(χ2 = 3.281, p = 0.070). The status of the primary tumor
and metastatic lesions could be evaluated in 58 of the 92
patients who had died. Of these, six cases had progressive
disease of the primary tumor without developing any new
metastases, and of these six cases, four involved a radi-
ation dose <40 Gy, seven cases had progressive disease of
the primary tumor and initial metastatic lesions, six cases
had progressive disease of the primary tumor and new
metastases, and 39 cases had new metastases in initially
involved or uninvolved organs.
The 1-, 2-, and 3-year OS rates for patients who re-
ceived a radiation dose ≥63 Gy to the primary tumor
compared with those who received a radiation dose
<63 Gy were 60.2 versus 26.2%, 21.8 versus 11.9% and
12.5 versus 4.0%, respectively and the MST was
15 months (95% CI, 11.9–18.1) versus 9 months (95%
CI, 6.6–11.4), respectively (χ2 = 11.038, p = 0.001). There
was a significant association between treatment response
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(complete remission + partial remission) had longer OS
than those without response (stable disease + progressive
disease) (χ2 = 4.364, p = 0.037). Radiation to metastatic sites
was not significantly correlated with OS in patients who
had both bone and other organ metastases (χ2 = 0.259,
p = 0.611). However, for patients with bone metastases
only and who received radiation to metastatic sites, there
was a trend towards a better OS (χ2 = 2.757, p = 0.097).
A radiation dose to primary tumor ≥63 Gy remained
significant for OS when patients with only bone metasta-
ses and those who had bone and other organ metastases
were analyzed separately. For patients with bone metas-
tases only, the 1-, 2- and 3-year OS rates were 68.1, 25.5
and 20.4%, respectively and the MST was 16 months (95%
CI, 14.1–17.9) for those who received radiation ≥63 Gy,
and the 1-, 2- and 3-year OS rates were 41.3, 23.6 and
7.9%, respectively for those who received radiation <63
Gy and the MST was 10 months (95% CI, 4.8-15.2)
(χ2 = 4.012, p = 0.045, Figure 1). For patients who had
bone both and other organ metastases, the 1-, 2- and
3-year OS rates were 52.1, 17.4 and 0.0%, respectively, and
the MST was 14 months (95% CI, 9.6–18.4) for those who
received radiation ≥63 Gy, whereas it was 26.6, 0.0 and
0.0%, respectively for those who received <63 Gy and
the MST was 7 months (95% CI, 4.8–9.2) (χ2 = 6.301,
p = 0.012, Figure 2).
The 1-, 2- and 3-year OS rates for T1-2 patients com-
pared with T3-4 were 50.0 versus 39.5%, 27.8 versus
9.3% and 18.5 versus 2.3%, respectively and the MST
was 14 months (95% CI, 9.6–18.4) versus 9 months (95%
CI, 6.1–11.9), respectively (χ2 = 3.912, p = 0.048). For pa-
tients with bone metastases only, patients with T1-2
tumors had longer OS than those with T3-4, and the 1-,
2- and 3-year OS rates were 66.7 versus 46.2%, 38.1 ver-
sus 10.8% and 25.4 versus 5.4%, respectively, and the
MST was 17 months (95% CI, 12.4–21.6) versus 11 months
(95% CI, 7.1–14.9), respectively (χ2 = 3.904, p = 0.048). For
patients who had both bone and other organ metasta-
ses, T-classification of the primary tumor was not cor-
related with OS (χ2 = 0.001, p = 0.962). Patients with a
KPS score >70 showed borderline significantly better OS
than those with a KPS equal to 70 (χ2 = 2.955, p = 0.086).
OS was significantly prolonged in patients who re-
ceived ≥4 cycles chemotherapy, and the 1-, 2- and 3-year
OS rates were 57.1, 20.3 and 11.6%, respectively, whereas
the OS rates were 27.2, 12.4 and 4.6% for those who re-
ceived <4 cycles, respectively, and the MST was
14 months (95% CI, 11.6–16.4) versus 8 months (95%
CI, 4.9–11.1) (χ2 = 6.800, p = 0.009), respectively. Simi-
larly, among patients who had both bone and other
organ metastases, OS was significantly prolonged in
those who had received ≥4 cycles of chemotherapy ver-
sus those who had received <4 cycles, and the MST was14 months (95% CI, 8.7-19.3) versus 6 months, respect-
ively (95% CI, 3.1–8.9) (χ2 = 9.706, p = 0.002). However,
this difference was not statistically significant in patients
with bone metastases only, and the MST was 14 months
(95% CI, 10.3–17.7) versus 12 months (95% CI, 6.8–17.2)
(χ2 = 0.756, p = 0.385). Univariate analysis revealed that
sex, age, pathology type and N stage were not associ-
ated with OS. Multivariate analysis revealed that a radi-
ation dose ≥63 Gy (p = 0.028) and bone metastases only
(p = 0.006) were independent prognostic factors for bet-
ter OS, and GTV (p = 0.056) and treatment response of
the primary tumor (p = 0.084) were marginally corre-
lated with OS (Table 2).
Discussion
This study sought to investigate whether combining sys-
temic chemotherapy with radiotherapy in the treatment
of the primary thoracic tumor could further improve
survival in NSCLC patients with bone metastases. The
results of the current study showed that radiotherapy
≥63 Gy to the primary tumor, and having only bone
metastatic disease were independent prognostic factors
for better OS in stage IV NSCLC patients treated with
concurrent chemoradiotherapy. Radiation dose to the
primary tumor ≥63 Gy remained significant when pa-
tients with bone metastases only and those with both
bone and other organ metastases were analyzed separ-
ately. In accordance with a previous publication [9], our
results also suggested that aggressive radiation to the
primary tumor may improve survival in a subset of such
NSCLC patients with bone metastases.
Lopez et al. reported that patients who had smaller
tumor volumes had longer OS [9]. Our results showed
that patients with a GTV <159 cm3 tended to have longer
OS than those with a GTV ≥159 cm3. On multivariate
analysis, GTV was marginally correlated with OS in this
study. Higginson et al. reported that the status of the pri-
mary tumor was associated with OS in NSCLC patients
with metastases [12]. For the subset of patients who had
bone metastases only, patients with T1-2 disease had lon-
ger OS than those with T3-4. The results from these stud-
ies suggest that the status of the primary tumor should be
taken under consideration; those with early T-stage and
small volume tumors may obtain more benefit from ag-
gressive radiation for their primary tumor. Radiation for
the metastases was not associated with OS in the current
study, probably because most of the patients (84%) did
not receive radiotherapy for their metastatic disease, thus
making it difficult to detect an advantage among patients
who received radiotherapy for metastatic disease; and for
most of the patients who received radiotherapy for their
metastatic disease, it was of a palliative nature.
Hellman et al. proposed the notion of oligometastases
to indicate the presence of limited metastases and
Figure 1 Comparison of overall survival curves at different radiation doses in patients with only bone metastases.
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between localized disease and widespread disease [13].
Aggressive therapy for the primary tumor and metastatic
lesions in NSCLC patients with oligometastases may pro-
duce better OS [9,10,14]. Our results also showed thatFigure 2 Comparison of overall survival curves at different radiationradiation to metastatic sites displayed a trend towards im-
proving OS in patients with only bone oligometastases.
The recommended number of chemotherapy cycles
for stage IV NSCLC is 4–6 according to the ASCO
guideline [15]. We then evaluated patients with anddoses in patients with metastases to both bone and other organs.
Table 2 Multivariate analysis of overall survival




T stage (T3-4 vs. T1-2) 1.368 0.863 2.168 0.182
GTV (<159 cm3 vs. ≥159 cm3) 0.564 0.314 1.014 0.056
KPS status (>70 vs. =70) 0.873 0.496 1.437 0.683
Thoracic radiation dose
(<63 Gy vs. ≥63 Gy)
1.649 1.056 2.576 0.028
Response of primary tumor
(SD + PD vs. CR + PR)
1.534 0.945 2.492 0.084
Chemotherapy (≥4 vs. <4 cycles) 0.804 0.507 1.274 0.353
Metastatic organ (bone with
other organs vs. bone only)
1.880 1.203 2.937 0.006
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separately. Univariate analysis showed that the number
of chemotherapy cycles was not correlated with OS for
patients who had bone metastases only. However, the
subset of patients who had both bone and other organ
metastases, and who had received ≥4 cycles of chemo-
therapy, had longer OS. Our findings suggest that the
status of the metastatic disease may also be used as a
criterion to decide the number of chemotherapy cycles
for patients with bone metastases, when they receive ra-
diation to the primary site.
There is a limitation of the current study in that the
imaging data of some patients were not gained to evalu-
ate patterns of failure and the relationship between OS
and local control of the primary tumor. Nearly 50% of
stage IV NSCLC patients experienced local recurrence
in initially involved sites, and local control and status of
the primary tumor has been associated with OS
[12,16,17]. Several publications have confirmed that a
higher radiation dose was associated with improved local
tumor control and OS in patients with NSCLC [9,18].
Although the relationship between OS and local tumor
control was not evaluated in this study, our results
showed that the higher radiation dose to the primary
tumor was correlated with OS. Thirteen of 58 patients
died owing to local recurrence accompanied by distant
metastases, and only six patients died of local recurrence
alone. Of these six cases, four involved a radiation dose
<40 Gy. These findings also suggest that the local dose
used for the primary tumor played an important role in
prolonging the survival of NSCLC patients with bone
metastases. Because of the retrospective nature of the
current study, a randomized trial is necessary to evaluate
the causal effect of radiation dose on OS.
The findings from the current study can be summa-
rized as follows. First, a higher radiation dose (≥63 Gy)
to the primary tumor was significantly associated with
better OS in both univariate and multivariate analysis.Second, although patients with only bone metastases
had better OS than those who had both bone and other
organ metastases, a higher radiation dose remained sig-
nificant when patients who had only bone metastases
and those who had both bone and other organ metasta-
ses were analyzed separately. Moreover, for patients who
had only bone metastases, the T-stage of their primary
tumor was associated with OS. In conclusion, aggressive
thoracic radiation plays an important role in improving
OS in NSCLC patients with bone metastases.
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